Sangamo Announces Closing of Biogen Collaboration Agreement
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Business Wire
- Sangamo has received $225 million in stock proceeds; will receive additional $125 million upfront license fee by May 8, 2020 BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. (Nasdaq: BIIB) and that the global licensing collaboration agreement with Biogen for the development and commercialization of gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases is now effective. Under the terms of the collaboration, Sangamo has received $225 million from the purchase by Biogen of newly issued Sangamo stock and will receive an upfront license fee of $125 million from Biogen no later than May 8, 2020. Additionally, Sangamo is eligible to earn up to $2.37 billion in other development, regulatory and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1.
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their RightsAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMOAccesswire
- SGMO ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Sangamo Therapeutics, Inc. investmentAccesswire
- Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to ConnectAccesswire
- SGMO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sangamo Therapeutics, Inc. Shareholders Who Lost MoneyAccesswire
SGMO
Earnings
- 11/12/24 - Beat
SGMO
Sec Filings
- 12/30/24 - Form 8-K
- 12/10/24 - Form 8-K
- 11/26/24 - Form 4
- SGMO's page on the SEC website